NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide ...

Pfizer wins a $10 billion deal for weight-loss drugmaker Metsera, ending its bidding war with Danish rival Novo Nordisk.

Danish drugmaker Novo Nordisk announced a partnership with Emcure Pharma on Monday to launch its Poviztra, semaglutide injection 2.4 mg, in India. Poviztra is the second brand of its weight loss drug ...

Novo Nordisk (NYSE:NVO) climbs about 2% on early Monday after it says it will not raise its offer for Metsera (NASDAQ:MTSR), ...

A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and ...

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.

Trump administration drug deals link U.S. prices to global lows, aiming to cut costs via Pfizer, AstraZeneca, and TrumpRx in 2026.

The announcement comes on the heels of a deal with the Trump administration to expand access to weight-loss drugs and reduce ...

After [losing out to Pfizer]( ...